Full-Time

Senior Data Scientist

Confirmed live in the last 24 hours

Formation Bio

Formation Bio

51-200 employees

Accelerates drug development using AI technology

Compensation Overview

$170k - $215k/yr

+ Equity + Generous Perks

Senior

Boston, MA, USA

Eligible remote locations include Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts, New Hampshire, New Jersey, North Carolina, Ohio, Pennsylvania, South Carolina, Texas, Utah, Virginia, and Washington, D.C.

Category
Data Science
Data Analysis
Data & Analytics
Required Skills
Python
Data Science
Requirements
  • PhD in computational sciences or life sciences
  • 3+ years of post-academic experience in life sciences (biotech, pharma, consulting)
  • Strong programming skills, particularly in Python
  • Extensive experience in multi-modal bioinformatics analysis
Responsibilities
  • Lead and execute complex data science projects that directly advance our drug development portfolio
  • Develop and implement sophisticated models for therapeutic hypothesis evaluation, including patient stratification and biomarker identification
  • Design and create AI models for modernizing clinical trial evaluations, including surrogate endpoints
  • Aid in the development and training of AI agents to automate and optimize biomedical workflows
  • Collaborate cross-functionally with clinical, technical, and research teams
  • Present complex analytical findings to senior stakeholders, including executive leadership
Desired Qualifications
  • Proven expertise in cloud computing environments, including proficiency with tabular and/or graph databases
  • Strong background in machine learning and deep learning, particularly in biological applications
  • Experience with large language models (LLM)
  • Demonstrated ability to collaborate effectively with engineering teams on production systems
  • Strong communication skills with proven ability to present complex technical findings to senior stakeholders

Formation Bio focuses on speeding up the process of developing new drugs by using its own AI-driven platform. This platform helps the company identify and acquire clinical-stage assets, which are drugs that are already in testing phases. By using flexible financing options, Formation Bio aims to lower the high costs and long timelines usually involved in bringing new medications to market. The company works with pharmaceutical and biotech firms to help them develop their drugs more quickly and efficiently. Unlike many competitors, Formation Bio emphasizes the use of advanced AI tools to improve drug selection and development processes. The ultimate goal is to make new treatments more accessible and affordable for patients.

Company Size

51-200

Company Stage

Series D

Total Funding

$530.3M

Headquarters

New York City, New York

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • $372M Series D funding boosts platform expansion and asset acquisition capabilities.
  • Collaboration with OpenAI and Sanofi advances AI-driven drug discovery standards.
  • Precision genomics partnership with SomaLogic improves biomarker identification and patient stratification.

What critics are saying

  • Competition from other AI-driven drug developers may impact market share.
  • Regulatory scrutiny on AI processes could lead to delays and compliance costs.
  • Dependence on partnerships poses risks if collaborations dissolve or underperform.

What makes Formation Bio unique

  • Formation Bio uses AI to accelerate drug development, reducing costs and timelines.
  • The company acquires clinical-stage assets, enhancing drug development flexibility and efficiency.
  • Partnerships with major pharma firms provide access to proprietary data and resources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-1%
Intelligence360
Jul 18th, 2024
Trialspark Dba Formation Bio Has Filed A Notice Of An Exempt Offering Of Securities To Raise $372,000,000.00 In New Equity Investment.

TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment. TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, TrialSpark dba Formation Bio is raising up to $372,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamine Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TrialSpark dba Formation BioFormation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.To learn more about TrialSpark dba Formation Bio, visit http://www.formation.bio/TrialSpark dba Formation Bio Linkedin Page: https://www.linkedin.com/company/formationbio/Contact:Benjamine Liu, Chief Executive Officer866-283-7544https://www.linkedin.com/in/benjamine-liu-54306518/SOURCE: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

Finsmes
Jun 26th, 2024
Formation Bio Raises $372M in Series D Funding

Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding

Hit Consultant
May 21st, 2024
Sanofi, Formation Bio, Openai Partner On Ai-Powered Drug Discovery

What You Should Know:– Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.– Sanofi, Formation Bio, and OpenAI believe this collaboration will be a game-changer in the pharmaceutical industry. By combining their expertise in data, AI technology, and drug development, they aim to revolutionize the way new medicines are discovered and brought to market.A Symphony of ExpertiseThe collaboration will combine the unique strengths of each partner:Sanofi: Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery.Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery. OpenAI: World-renowned for its advancements in AI technology, OpenAI will contribute access to cutting-edge AI capabilities

PR Newswire
Jan 10th, 2022
Trialspark partners with SomaLogic, Inc.

TrialSpark is also partnering with industry leaders such as SomaLogic to leverage precision genomics and proteomics platforms to identify key biomarkers and stratify patients using synovial fluid samples from prior clinical studies using AI and machine-learning approaches.

CB Insights
Oct 5th, 2021
Trialspark partnered with SANOFI PASTEUR on Aug 6th 18'.

TrialSpark has collaborated with pharma companies such as Sanofi, Novartis, and Pfizer, among others.